The vaccine (CDX-1401) is a full-length NY-ESO-1 tumor antigen conjugated to a fully human monoclonal antibody with specificity for the dendritic cell receptor DEC-205 combined with poly-ICLC (Hiltonol).30 This evidence concerns the gene LY75 and neoplasm.